Please ensure Javascript is enabled for purposes of website accessibility

Sorrento Therapeutics Opened Up 11.7% After CEO Slams Short Sellers

By Brian Orelli, PhD – Aug 26, 2020 at 2:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech's valuation could be important in the short term.

Most companies don't comment on outside reports. Sorrento Therapeutics' (SRNE -6.51%) President and CEO Henry Ji even says that's generally the biotech's policy.

Then he went off on short sellers in an interview posted in a tweet by RagingBull yesterday afternoon.

"I am giving them a fair warning shot. Just cover yourself, don't ruin your family," Ji said of short sellers who he says are trying to manipulate Sorrento's stock.

Investors seem to buy the message. Shares opened up 11.7% today, although the gains have pared back to a gain of just 1.8% at 1:43 p.m. EDT.

Sorrento's share price has been on a roller coaster, ending last year at $3.38, climbing as high as $19.39 on the heels of potential treatments, tests, and a vaccine for COVID-19, only to see shares subsequently cut in half.

Hand holding a positive coronavrius blood sample.

Image source: Getty Images.

On the surface, Ji and long-term investors don't need to worry about people shorting the stock or whether it's being manipulated. In the long run, Sorrento's value will be determined by whether it can bring one or more products to market and ultimately the profits from those products.

But in the short term, Sorrento's valuation is important because the higher the valuation, the more money it can raise through selling its shares in secondary offerings. As the valuation falls, current investors experience more dilution if the company wants to raise the same amount of capital.

Sorrento ended the second quarter with $24.4 million in cash and equivalents, so it seems likely the company will need to raise cash in the not-too-distant future -- which may explain Ji's rant.

Brian Orelli, PhD and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sorrento Therapeutics, Inc. Stock Quote
Sorrento Therapeutics, Inc.
SRNE
$1.58 (-6.51%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.